Rapid communications in mass spectrometry : RCM · 2025
Transcriptomic and Metabolomic Mechanism of Ibuprofen, Chondroitin Sulfate, and Vitamins With Minerals Tablets (21) for Kashin-Beck Disease Treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wen Jinfeng, Deng Xingxing, Yang Zhengjun, Niu Hui, Zhang Qian, Zhao Yijun, Naren Gaowa, Liu Huan, Zhang Feng, Yang Xiaodong, Wu Cuiyan
Аннотация
BACKGROUND: Kashin-Beck disease (KBD) is an osteoarthropathy with no specific drug treatment. This study seeks to uncover the molecular mechanisms of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) in treating KBD.
METHODS: Integrated transcriptomic and metabolomic analyses were performed on peripheral blood samples collected from four KBD patients before and 1 month after treatment. Differential gene expression was assessed using the DESeq package, while differential metabolites were identified through univariate and multivariate statistical analyses.
RESULTS: After treatment, 5671 differential genes (|log2FC| ≥ 1, q < 0.05) were identified, with 4954 upregulated and 717 downregulated. Enriched pathways included PI3K-Akt, MAPK, ECM-receptor interaction, Rap1, and Ras signaling. Untargeted metabolomics analyses revealed five differentially expressed metabolites (VIP ≥ 1, |log2FC| > 0.58, p < 0.05): L-glutamine, 2-methylpropan-2-amine, epsilon-caprolactam, phosphocholine, and 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine. Metabolite enrichment analysis suggested alterations in amino acid and fatty acid metabolism. Integrated analysis revealed key pathways such as alanine, aspartate, and glutamate metabolism and arginine biosynthesis.
CONCLUSIONS: The combination of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) may alleviate KBD through modulation of key genes (GDNF, BDNF, CCL2, VEGFA, and PPARG) and glutamine-related metabolic pathways.
METHODS: Integrated transcriptomic and metabolomic analyses were performed on peripheral blood samples collected from four KBD patients before and 1 month after treatment. Differential gene expression was assessed using the DESeq package, while differential metabolites were identified through univariate and multivariate statistical analyses.
RESULTS: After treatment, 5671 differential genes (|log2FC| ≥ 1, q < 0.05) were identified, with 4954 upregulated and 717 downregulated. Enriched pathways included PI3K-Akt, MAPK, ECM-receptor interaction, Rap1, and Ras signaling. Untargeted metabolomics analyses revealed five differentially expressed metabolites (VIP ≥ 1, |log2FC| > 0.58, p < 0.05): L-glutamine, 2-methylpropan-2-amine, epsilon-caprolactam, phosphocholine, and 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine. Metabolite enrichment analysis suggested alterations in amino acid and fatty acid metabolism. Integrated analysis revealed key pathways such as alanine, aspartate, and glutamate metabolism and arginine biosynthesis.
CONCLUSIONS: The combination of ibuprofen, chondroitin sulfate, and vitamins with minerals tablets (21) may alleviate KBD through modulation of key genes (GDNF, BDNF, CCL2, VEGFA, and PPARG) and glutamine-related metabolic pathways.